Latest Investments News

Scalare Partners reported a remarkable 231% revenue increase in Q2 FY26, driven by full integration of recent acquisitions and new ecosystem initiatives. The company also turned operating cashflow positive, signalling strong momentum ahead.

Greatland Resources capped off 2025 with robust gold and copper production at Telfer, generating $406 million in operating cash flow, while its Havieron feasibility study confirmed a world-class, low-cost gold-copper mine with a $4.2 billion pre-tax NPV.

Develop Global Limited reports strong December quarter progress with Woodlawn mine commissioning on track, a major contract win, and a significant value uplift at Sulphur Springs ahead of a mid-2026 investment decision.

LTR Pharma has marked a key milestone with over 1,000 SPONTAN prescriptions under Australia’s Special Access Scheme and is advancing clinical trials and US market preparations for its erectile dysfunction treatments.

Develop Global Limited reported a positive operating cash flow of AUD 18.8 million for the December 2025 quarter, maintaining robust liquidity despite significant investing and financing cash outflows.

St George Mining has appointed a top Washington DC government relations firm to deepen its engagement with US agencies, advancing its Araxá rare earths project amid growing US efforts to secure critical mineral supply chains in the Western Hemisphere.

29Metals Limited has initiated a fully underwritten $150 million entitlement offer at $0.40 per share, aiming to bolster its growth projects and operational recovery following seismic disruptions. The retail offer opens on 28 January and closes on 11 February 2026.

Bioxyne Limited has posted a record $17.2 million in quarterly revenue for Q2 FY26, driven by strong growth in its cannabis and psychedelics segments alongside strategic international expansions.

Tetratherix Limited (ASX, TTX) reports significant progress in clinical trials, strategic partnerships, and manufacturing capacity, positioning itself for near-term commercialisation and sustained innovation.

Coronado Global Resources reported a solid FY25 with increased saleable production and reduced mining costs, underpinned by key expansions and refinancing deals that set the stage for stronger cash flow in 2026.

Following its December 2025 ASX debut and a successful IPO, Saluda Medical reports robust global revenue growth and expands its US sales force, prompting an upward revision of its FY26 revenue guidance.

Beforepay Group reported a 17% rise in advances and an 18% increase in revenue for Q2 FY26, while profit fell sharply due to holiday-season defaults and strategic investments.